Press

1. IntelliDose Launches IntelliScribe March 2, 2010
2. IntrinsiQ Sharpens Cancer Treatment Analysis February 10, 2010
3. Dayton Physicians Commits to Clinical Excellence by Partnering with IntelliDose February 2, 2010
4. IntelliDose Exhibiting at Fifth Annual Community Oncology Conference February 5–6, 2010
5. New York cancer care center uses automation to handle coding, reimbursement January 29, 2010
6. Tarceva Reprieve? FDA Delay Could Mean Little Either Way January 25, 2010
7. WWMR Vice President Invited to Speak at PBIRG Fall Biotech Workshop December 7, 2009
8. Panel Advises on Clinical Pathways: What, Why, and How November, 2009
9. IntrinsiQ Expands Executive Team November 3, 2009
10. IntelliDose Exhibiting at North Carolina Oncology Management Society 2009 Fall Conference November 18 to 20, 2009
11. Opportunity reconsidered: maintenance therapy in oncology October, 2009
12. IntrinsiQ Study: Oncologists Overlook Maintenance Therapy Option – More Often than They Realize September 15, 2009
13. Industry Thought Leaders: A Discussion with Jeff Forringer, President of IntrinsiQ, LLC August 2009
14. Are CPOEs worth the investment? August 2009
15. Information Technology: Tracking the Evolution of Oncology Drug Prescribing August 2009
16. Rich Gray, General Manager of IntelliDose, to Speak at ACCC 26th National Oncology Economics Conference September 22 to 25, 2009
17. IntelliDose Exhibiting at eClinicalWorks 2009 National Users Conference September 12 to 15, 2009
18. Jeff Forringer, President of IntrinsiQ, to Speak at the Magellan/ICORE 6th Annual Oncology Summit September 11, 2009
19. IntelliDose Exhibiting at GE Centricity User Group Fall Conference August 28 and 29, 2009
20. How Much Should Cancer Drugs Cost: Landmark Cornell University Study Sheds New Light on Old Assumptions August 4, 2009
21. IntrinsiQ Sponsors Cancer Center Business Summit October 8-9, 2009
22. The First Step to a Paperless Practice July 1, 2009
23. On the Move – Spotlight on Jeff Forringer June 19, 2009
24. Specialized chemotherapies increase market share, cost of care June 2009
25. IntrinsiQ Acquires Market Research Firm WWMR June 9, 2009
26. IntrinsiQ Appoints New Executive Team May 12, 2009
27. IntrinsiQ's IntelliDose May 2009
28. The real cost of treating off-label and off-guidelines March 2009
29. NewsMakers March 2009
30. Small mistakes, huge consequences; Onc-specific software improves safety February 2009
31. Safe Handling; The Right Drug, Right Dose, Right Patient January/February 2009
32. Automated Oncology February 2009
33. Still Using Paper and Pen? January 2009
34. OnCare Hawaii Selects IntelliDose for Oncology Patient Safety and Practice Efficiency January 6, 2009
35. Safe Handling December 2008
36. Market Opportunity in Lung Cancer December 2008
37. Cancer Center of South Florida Selects IntelliDose for All-Electronic Practice November 3, 2008
38. IntrinsiQ Launches IntelliDose 3.8 October 27, 2008
39. Technology: Can Oncology EMRs Improve Quality? September 2008
40. IntrinsiQ Builds Out Its Oncology-Products Market Analytics September 2008
41. IntrinsiQ Wins 3 Top Honors from Inc. Magazine September 9, 2008
42. New Reporting from IntrinsiQ Measures Impact of Key Events on Oncology Drug Usage September 2, 2008
43. High Drug Costs a Factor in Cancer Care August 28, 2008
44. Pharmawire analysis: Cyclacel's seliciclib comes under physician scrutiny August 2008
45. DSS Licenses IntelliDose to Standardize VA Oncology Practices August 18, 2008
46. Buried Treasure June 23, 2008
47. Data from the Doctor April 15, 2008
48. IntrinsiQ LLC - Dose of Success March 7, 2008
49. IntelliCost Provides Cost of Therapy Insight for Sizing New Market Opportunities February 13, 2008
50. Software application aims to eliminate human error in chemotherapy dosing January 11, 2008
51. Oncologists Nationwide Choose IntelliDose for Clinical Safety and Efficiency November 28, 2007
52. IntrinsiQ Expands Oncology’s Gold-Standard for Patient Data Collection September 25, 2007
53. IntelliDose to Participate in ASCO EHR Symposium July 19, 2007
54. GE Healthcare and IntrinsiQ Announce Collaboration to Link Clinical Oncology Information within Patient Electronic Medical Records May 31, 2007
55. IntelliDose® Unveils IntelliCharge — Automated Encounter Charge Capture Improves Control and Billing of Costly Chemotherapy Drugs May 31, 2007
56. PRA International and IntrinsiQ Research Enter Exclusive Agreement for Oncology Patient Treatment Data March 19, 2007
57. Pulse and IntrinsiQ Sign Strategic Agreement January 16, 2007
58. IMS, IntrinsiQ Research Establish Strategic Alliance to Deliver Global, Clinically Rich Oncology Market Intelligence August 2, 2006
59. Accel-KKR Acquires Majority Stake in IntrinsiQ June 20, 2006

FOR IMMEDIATE RELEASE:

DSS Licenses IntelliDose to Standardize VA Oncology Practices

IntrinsiQ’s Clinical Software Automates Chemotherapy Dosing and Sets Best-in-Class Standards for Cancer Care

JUNO BEACH, Fla. and WALTHAM, Mass. (Aug. 18, 2008) — IntrinsiQ, LLC, the oncology practice experts, and DSS, Inc. today announced a major licensing deal to provide a customized version of IntrinsiQ’s flagship clinical software -- IntelliDose® -- to more than 130 oncology departments across the expansive U.S. Department of Veterans Affairs (VA) hospital network.

The software, to be marketed as VistA Chemotherapy Manager (VCM)™, calculates, manages and tracks complex chemotherapy regimens to standardize treatment decisions and streamline operational practices. It produces legible, complete, and electronically verified orders to ensure dosing accuracy.

The deal expands a five-year relationship of VA hospitals using IntelliDose to manage the chemotherapy treatment of thousands of veterans. Through this new deal, DSS, the leading provider of integrated software packages to the VA, will customize and integrate IntelliDose into the VA’s VistA® health information system suite to ensure seamless patient information sharing and that the highest standards of care are met.

“The oncology specialty is a science of precise calculations and constant adjustments to regimens, requiring detailed documentation that needs to be shared across large clinical teams,” said Mark Byers, president of DSS. “IntelliDose is proven to meet the very specific needs of oncology treatment, while establishing best-practices for the best patient care possible.”

The VA joins more than 500 oncologists at leading hospitals, health networks and private practices that rely on IntelliDose to treat more than 19,500 patients each month. The computerized physician order entry (CPOE) solution eases oncologists’ transition from paper and pen to the electronic health record by adapting to the existing workflow of a practice while automating the management of essential chemotherapy lines-of-treatment.

“Oncologists have never had more challenges. There are more patients to treat within the same office hours, more treatment options to choose from and far greater complexity in dosing,” said Ted Owens, division general manager of IntrinsiQ’s IntelliDose software division. “VCM will remove the complexity and potential for errors in hand-calculated chemotherapy regimens while institutionalizing optimal treatment decisions for our nation’s veterans.”

About DSS, Inc.

DSS, Inc. has provided VistA integrated administrative and clinical software applications to the VA since 1994. These include billing, coding, dental, document imaging, fee basis claims processing, medical charting, mental health, patient registration, radiology decision support, release of medical information, telecare triage, and voice recognition. In addition, DSS, Inc. has integrated administrative and clinical medical software applications of over a dozen other companies with VistA. DSS, Inc. is also one of seven contract holders of the VA’s VistA Contractor Support (VCS) blanket purchase agreement (BPA). The VCS vendors provide contracted software maintenance and support of the 110 modules which comprise VistA. For more information, please visit www.dssinc.com.

About IntrinsiQ

IntrinsiQ, LLC is the leading provider of medical oncology workflow solutions and the premier source of US oncology data and analysis. Each month, IntrinsiQ’s market leading software application, IntelliDose®, captures the treatment decisions and details from more than 500 oncologists, for more than 19,500 unique patients, and regarding more than 128,000 drug administrations. The IntrinsiQ database is unrivaled in accuracy, detail and timeliness of information about the medical oncology care process. This database is the foundation of products and services that uniquely address the business information needs of pharmaceutical product managers, market researchers and financial analysts. For more information, please visit www.intrinsiq.com.

IntrinsiQ Company Contact:

Ted Owens
(781) 434-3331
ted.owens@intrinsiq.com

IntrinsiQ Media Contact:

Lesley Cannata
(617) 969-9192
lcannata@corporateink.com

DSS Company Contact:

Mark Byers
(561) 227-0207
mbyers@dssinc.com

DSS Media Contact:

Mike Ginsburg
(561) 472-5672
mginsburg@dssinc.com

© 2010 IntrinsiQ, LLC